Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 23, 2009 Rich Smith	This Just In: Upgrades and Downgrades Soleil Securities initiates coverage of three oil stocks. Here is an analysis of their recommendations.
The Motley Fool December 17, 2009 Rich Smith	This Just In: Upgrades and Downgrades Big Pharma stocks get a thumbs up from UBS.
The Motley Fool November 17, 2008 Rich Smith	This Just In: Upgrades and Downgrades Bank of America analysts aren't terribly impressed with most drug companies. But they did give thumbs up to two.
The Motley Fool February 4, 2010 Rich Smith	This Just In: Upgrades and Downgrades Soleil Securities says that Kraft is a company that will outgrow the foods industry as a whole and earn higher profit margins than its rivals -- yet right now trades at a discount to the industry's valuation.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool June 30, 2010 Rich Smith	This Just In: Upgrades and Downgrades Major Wall Street investment house Soleil Securities downgraded Eli Lilly shares to "sell."
The Motley Fool September 14, 2009 Rich Smith	This Just In: Upgrades and Downgrades Soleil Securities turns out the light on First Solar, downgrading the stock to "sell."
The Motley Fool January 26, 2009 Brian Orelli	Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place.
The Motley Fool August 29, 2008 Brian Orelli	Can Health-Care Dividends Hold Up? As many health-care companies' share prices drop, their dividend yields have become strikingly attractive. The big question, though, is whether these dividends can hold up.
The Motley Fool December 16, 2008 Brian Orelli	Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool September 21, 2009 Rich Smith	This Just In: Upgrades and Downgrades All-Star analyst Soleil Securities hops off the fertilizer wagon, predicting a slower-than-expected recovery in potash demand.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool August 26, 2010 Jordan DiPietro	Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling.
The Motley Fool July 29, 2009 Rich Smith	This Just In: Upgrades and Downgrades All-Star analyst Kaufman Bros. upped its price target on Salesforce.com, the cloud computing company. The stock dropped regardless.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool June 11, 2008 Brian Orelli	Dueling Fools: Pfizer Bull The bullish opinion on Pfizer is that this may be the best time to buy this stock.
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool May 19, 2009 Selena Maranjian	Frightening News About Dividend Stocks For dividend lovers, the past year has been brutal. Dividend cuts have come at the fastest pace in 50 or more years. Check out some of these not-so-obscure companies that have cut their dividend in the past 12 months.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
The Motley Fool March 23, 2011 Todd Wenning	Dividend Report Card: Pfizer Investors considering Pfizer as a dividend play should decide if the combination of 4% current yield and low- to mid-single-digit dividend growth potential is a better deal than other pharmaceutical shares are offering.
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Back to the Future at Pfizer Pfizer just provided guidance for the next couple of years. The news shows that the company is willing to shake things up, but investors should remain skeptical until tangible benefits occur.
The Motley Fool October 21, 2008 Brian Orelli	The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool January 13, 2005 Selena Maranjian	Big Dividend Payers Big dividend payers can reward you well, but select carefully.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool February 8, 2010 Selena Maranjian	Good News About the Worst Year It's over. Remember, the overall trend of the market is up. When stocks of good, healthy, and growing companies get beaten down, they're likely to regain their footing.
The Motley Fool July 20, 2006 Stephen D. Simpson	Pfizer's Big Plans Between the launch of inhaled insulin and spending $34 billion, Pfizer has a lot on its plate. Investors, take note.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
The Motley Fool May 12, 2010 Selena Maranjian	3 Signs of a Strong Dividend Not all dividends are created equal. Here's how to find the best candidates for your portfolio.
The Motley Fool May 19, 2010 Selena Maranjian	You Can Have Tech and Dividends Many investors believe that they have to choose between slow-growing, dividend-paying blue chips, or rapidly expanding, payout-free tech companies. That used to be the case -- but not anymore.
The Motley Fool February 26, 2010 John Rosevear	6 Cheap Stocks That Keep Paying You Back Never underestimate the power of dividends.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool May 17, 2004 Roger Nusbaum	Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market?
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
The Motley Fool November 7, 2011 Dan Caplinger	Has Pfizer Become the Perfect Stock? The pharma giant still faces the challenge of patent expirations that could outpace its pipeline development.
The Motley Fool August 30, 2010 Ilan Moscovitz	Pfizer: Dividend Dynamo or Disaster? The stability and growth of Pfizer's dividend will depend on its ability to continue to develop and grow its pipeline of drugs and successfully integrate Wyeth.
The Motley Fool October 24, 2007 Selena Maranjian	Meet the Dividend Achievers If you're looking for dividend-paying stocks, you need to know the Mergent Dividend Achievers.
The Motley Fool May 3, 2006 Selena Maranjian	When Dividends Are Dicey A hefty dividend yield isn't always something investors can count on.
The Motley Fool July 27, 2010 Selena Maranjian	New Taxes Can't Stop These Dividends Even if the IRS raises rates, dividends remain potent portfolio powerhouses.
BusinessWeek January 10, 2005 Amy Barrett	Pfizer Has Plenty Of Pain To Kill Many investors and analysts argue that while the drug company should continue to plow money into new-drug development, the company needs to aggressively reduce other costs and return greater amounts of cash to shareholders through a higher dividend.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool December 24, 2007 Rick Aristotle Munarriz	4 Stocks That Took a Hike These stocks recently raised their dividends: Pfizer... Eli Lilly... Moody's... Waste Management...
The Motley Fool December 14, 2005 Steven Mallas	Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way.
The Motley Fool June 23, 2009 Selena Maranjian	Look Beyond the Usual Suspects for Profits Do keep dividends in mind when shopping for your portfolio -- but don't limit yourself to any one list of stocks.